# Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

> **NCT00299884** · — · COMPLETED · sponsor: **Queen's University** · enrollment: 45 (actual)

## Conditions studied

- Dyslipidemia
- Vascular Disease

## Interventions

- **DRUG:** Lipitor 20 mg
- **DRUG:** Combination Ezetrol 10 mg and Lipidil Supra 160 mg

## Key facts

- **NCT ID:** NCT00299884
- **Lead sponsor:** Queen's University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299884, "Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00299884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*